Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 456 clinical trials
None
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

+ ipilimumab alone in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

metastatic melanoma
ct scan
measurable disease
ipilimumab
BRAF
  • 11 views
  • 01 May, 2021
  • 52 locations
None
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma

systemic therapy
combinations
NRAS
metastatic melanoma
cytotoxic t-lymphocyte antigen 4
  • 0 views
  • 27 Jul, 2021
  • 35 locations
None
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma

systemic therapy
measurable disease
mek inhibitor
ipilimumab
combinations
  • 19 views
  • 05 Mar, 2021
  • 32 locations
None
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma …

advanced melanoma
metastatic melanoma
alopecia
cancer
pembrolizumab
  • 0 views
  • 17 Oct, 2021
  • 32 locations
None
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Substudy 02C is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02C is to evaluate the safety and efficacy of investigational treatment arms in participants with Stage III melanoma …

stage iii melanoma
alopecia
cancer
pembrolizumab
mk-3475
  • 0 views
  • 16 Oct, 2021
  • 25 locations
None
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Substudy 02B is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02B is to evaluate the safety and efficacy of investigational treatment arms in participants with 1L advanced melanoma …

advanced melanoma
metastatic melanoma
alopecia
cancer
pembrolizumab
  • 0 views
  • 15 Oct, 2021
  • 29 locations
None
War on Melanoma Public Health & Education Campaign

This trial studies how well a health educational campaign works in increasing early detection of melanoma in Oregon. The health educational campaign may provide information to help people learn about the early signs of melanoma. Increased education in Oregon may decrease the number of people who die from melanoma and …

  • 0 views
  • 04 Jul, 2021
  • 1 location
None
Encorafenib and Binimetinib Plus Pembrolizumab Versus Pembrolizumab for BRAF V600E/K Positive Melanoma

This is a randomized, double-blind, placebo-controlled, Phase 3 study to compare the efficacy, safety, and tolerability of encorafenib and binimetinib plus pembrolizumab (Triplet Arm) versus placebo plus pembrolizumab (Control Arm) in participants with metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma.

advanced melanoma
systemic therapy
measurable disease
melanoma skin
malignant melanoma of skin
  • 0 views
  • 29 Sep, 2021
  • 21 locations
None
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

Substudy 02D is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02D is to evaluate the safety and efficacy of investigational treatment arms in programmed cell-death 1 (PD-1) nave …

brain metastases
metastatic melanoma
metastasis
cancer
pembrolizumab
  • 0 views
  • 16 Oct, 2021
  • 15 locations
None
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

advanced/metastatic melanoma. The study consists of a Safety Run-in Phase to determine the RDE (recommended dose in expansion), followed by an Expansion Phase.

cancer
neutrophil count
melanoma skin
malignant melanoma of skin
metastatic melanoma
  • 16 views
  • 23 May, 2021
  • 26 locations